Singapore Clinical Trial: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National Cancer Centre National University Hospital

Trial Status: NA

Principal Investigator(s): Dr Amit Jain Dr Ross Soo

Published by HT Digital Content Services with permission from Health Daily Digest....